MedTrace Logo

High Density Lipoprotein Turnover

NCT00408148 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2010-12-10

No results posted yet for this study

Summary

The objective of the study is to evaluate the effect of Rimonabant 20mg in comparison to placebo, on HDL and VLDL lipoprotein kinetics, over a 12 months period.

Primary objectives:

* To assess effect of Rimonabant on HDL ApoA-I fractional catabolic rate (FCR).

Secondary objectives:

* To assess effect of Rimonabant on HDL ApoA-I production rate (PR) and on other lipoprotein kinetics.
* To assess effect of Rimonabant on lipids, glycemic and inflammatory parameters
* To assess effect of Rimonabant on body composition
* To assess safety of Rimonabant

Conditions

Interventions

DRUG

Placebo

Undistinguishable placebo tablets

DRUG

Rimonabant

White film-coated, for oral administration containing 20 mg of active rimonabant

Sponsors & Collaborators

Principal Investigators

  • Valérie Pilorget · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Australia
  • Finland
  • France
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00408148 on ClinicalTrials.gov